← brief for 2026-08-10 · Slowing decline

Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This combines many studies (a meta-analysis) of GLP-1 drugs — the class that includes Ozempic — in people with kidney failure, including those on dialysis. It weighed how safe and how effective these drugs are for this group. Pooling many studies is the strongest kind of evidence for whether they can be used safely here.

Who did this work

Dutta D · Jena S · Mahajan K · Kamrul-Hasan ABM · Bhattacharya S · Mohindra R

Source

Journal article · PubMed — the drug frontier · 2026 Aug 4
https://pubmed.ncbi.nlm.nih.gov/42551699/